This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Linoleic acid
- DrugBank Accession Number
- DB14104
- Background
Not Available
- Type
- Small Molecule
- Groups
- Approved, Experimental
- Structure
Structure for Linoleic acid (DB14104)
- Weight
- Average: 280.4455
Monoisotopic: 280.240230268 - Chemical Formula
- C18H32O2
- Synonyms
- (9Z,12Z)-Octadecadienoic acid
- (Z,Z)-9,12-octadecadienoic acid
- 9-cis,12-cis-Octadecadienoic acid
- 9Z,12Z-octadecadienoic acid
- acide cis-linoléique
- acide linoléique
- ácido linoleico
- all-cis-9,12-octadecadienoic acid
- C18:2 9c, 12c omega6 todos cis-9,12-octadienoico
- cis,cis-9,12-octadecadienoic acid
- cis,cis-linoleic acid
- LA
- Linolic acid
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Associated Therapies
- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Potassium linolate 3S022W5099 3414-89-9 BAYJYBALPIYBQQ-NBTZWHCOSA-M Sodium linolate 872C9A1W9I 822-17-3 WYPBVHPKMJYUEO-NBTZWHCOSA-M - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Bio-efa Borage Gla 240 Cap Linoleic acid (378 mg) + Gamolenic acid (240 mg) + Vitamin E (10 unit) Capsule Oral Pge Canada (86) Inc. 1989-12-31 2006-06-19 Canada 
Bio-efa Borage Gla 90 Cap Linoleic acid (216 mg / cap) + Gamolenic acid (90 mg / cap) + Vitamin E (10 unit / cap) + alpha-Linolenic acid (1 mg / cap) Capsule Oral Pge Canada (86) Inc. 1989-12-31 2006-06-19 Canada Black Currant Seed Oil Cap Linoleic acid (78 mg) + Gamolenic acid (41 mg) + Vitamin E (10 unit) Capsule Oral Pure Life International Prods Inc. 1993-12-31 2001-08-07 Canada Borage Oil Capsules Linoleic acid (375 mg) + Gamolenic acid (258 mg) + Oleic Acid (148 mg) + Palmitic Acid (96 mg) Capsule Oral General Nutrition Canada Inc. 2001-10-15 2009-08-05 Canada Borage Oil Capsules Linoleic acid (220 mg) + Borage oil (500 mg) + Gamolenic acid (125 mg) Capsule Oral Bioforce Canada Inc. 1994-12-31 1999-10-14 Canada Dr.Different VITAACNAL TX Capsule Serum Linoleic acid (0.76 g/30mL) + Nicotinamide (1.5 g/30mL) Liquid Topical Dareun Cosmetics Co., Ltd. 2021-12-01 Not applicable US 
Evening Primrose Oil + Vit E Cap Linoleic acid (375 mg) + Gamolenic acid (45 mg) + Vitamin E (15 unit) Capsule Oral Bioforce Canada Inc. 1993-12-31 2000-03-21 Canada Evening Primrose Oil Cap Linoleic acid (350 mg) + Gamolenic acid (40 mg) + Vitamin E (14.9 unit) Capsule Oral Pure Life International Prods Inc. 1992-12-31 2001-08-07 Canada Evening Primrose Oil Cap 500mg W Vit E Linoleic acid (350 mg) + Gamolenic acid (40 mg) + Vitamin E (14.9 unit) Capsule Oral Stanley Pharmaceuticals, A Division Of Vita Health Products Inc. 1990-12-31 2002-07-31 Canada Flaxseed Oil Capsules Linoleic acid (144 mg) + Oleic Acid (165 mg) + Palmitic Acid (54 mg) + alpha-Linolenic acid (594 mg) Capsule Oral General Nutrition Canada Inc. 1998-05-27 2007-08-01 Canada - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Cavan One Linoleic acid (30 mg/1) + Calcium (150 mg/1) + Calcium ascorbate dihydrate (25 mg/1) + Cholecalciferol (170 [iU]/1) + DL-alpha tocopheryl acetate (30 [iU]/1) + Doconexent (260 mg/1) + Ferrous asparto glycinate (7 mg/1) + Folic acid (1 mg/1) + Icosapent (40 mg/1) + Iron (20 mg/1) + Pyridoxine hydrochloride (25 mg/1) + alpha-Linolenic acid (30 mg/1) Capsule, gelatin coated Oral Seton Pharmaceuticals 2009-10-30 2011-11-27 US Dr.Different VITAACNAL TX Capsule Serum Linoleic acid (0.76 g/30mL) + Nicotinamide (1.5 g/30mL) Liquid Topical Dareun Cosmetics Co., Ltd. 2021-12-01 Not applicable US Lancell Slimming Linoleic acid (2.5 mL/100mL) + Stypocaulon scoparium (2 mL/100mL) Gel Topical MICELLBio Co., Ltd 2010-08-19 Not applicable US PrimaCare Linoleic acid (50 mg/1) + Biotin (1 mg/1) + Calcium ascorbate dihydrate (25 mg/1) + Calcium carbonate (100 mg/1) + Cholecalciferol (1000 [iU]/1) + Folic acid (1 mg/1) + Magnesium oxide (50 mg/1) + Nicotinamide (10 mg/1) + Omega-3 fatty acids (420 mg/1) + Potassium Iodide (150 ug/1) + Pyridoxine (50 mg/1) + Riboflavin (1.5 mg/1) + Zinc (15 mg/1) + alpha-Tocopherol acetate (15 [iU]/1) Pill Oral Avion Pharmaceuticals, Llc 2017-01-23 Not applicable US SIMILAC ALIMENTUM 400 G TOZ Linoleic acid (0.54 g/100ml) + Arachidonic Acid (0.013 g/100ml) + Doconexent (0.007 g/100ml) + alpha-Linolenic acid (0.058 g/100ml) ABBOTT LABORATUARLARI İTHALAT İHRACAT VE TİC. LTD. ŞTİ. 2020-08-14 Not applicable Turkey 
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 9KJL21T0QJ
- CAS number
- 60-33-3
- InChI Key
- OYHQOLUKZRVURQ-HZJYTTRNSA-N
- InChI
- InChI=1S/C18H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h6-7,9-10H,2-5,8,11-17H2,1H3,(H,19,20)/b7-6-,10-9-
- IUPAC Name
- (9Z,12Z)-octadeca-9,12-dienoic acid
- SMILES
- CCCCC\C=C/C\C=C/CCCCCCCC(O)=O
References
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0000673
- KEGG Compound
- C01595
- ChemSpider
- 4444105
- BindingDB
- 22231
- 6400
- ChEBI
- 17351
- ChEMBL
- CHEMBL267476
- ZINC
- ZINC000004474613
- PDBe Ligand
- EIC
- Wikipedia
- Linoleic_acid
- PDB Entries
- 1igz / 2evl / 2q9s / 4dq4 / 4ia6 / 4lkt / 4nyq / 5bvs / 5z0b / 6cng … show 27 more
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Supportive Care Malnutrition 1 4 Completed Treatment Patients Requiring Home Parenteral Nutrition 1 3 Completed Treatment Gastrointestinal Tract Cancer 1 2 Completed Prevention Parenteral Nutrition n-3 Fatty Acids / Preterm, Infant 1 2, 3 Active Not Recruiting Treatment Neuroaxonal Dystrophy, Infantile 1 1 Terminated Treatment Multiple Sclerosis 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Capsule, gelatin coated Oral Liquid Topical Liquid Oral Gel Topical Injection, emulsion Intravenous Tablet, coated Oral Pill Oral Capsule Oral - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.000154 mg/mL ALOGPS logP 7.06 ALOGPS logP 6.42 Chemaxon logS -6.3 ALOGPS pKa (Strongest Acidic) 4.99 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 2 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 37.3 Å2 Chemaxon Rotatable Bond Count 14 Chemaxon Refractivity 88.52 m3·mol-1 Chemaxon Polarizability 35.86 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Drug created at June 21, 2018 16:16 / Updated at September 28, 2021 21:54